SCHEMBL2916623

SCHEMBL2916623

CCOC(=O)CC1C[N]CCCN1

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.36
POLB P06746 2/20 0.36
SMN1; SMN2 Q16637 1/20 0.33
MGAM O43451 1/20 0.33
GAA P10253 1/20 0.33
SI P14410 1/20 0.33
MGAM2 Q2M2H8 1/20 0.33
KMT2A Q03164 3/20 0.32
ALDH1A1 P00352 2/20 0.32
TRPA1 O75762 1/20 0.32
SLC6A2 P23975 3/20 0.32
SLC6A3 Q01959 3/20 0.32
SLC6A4 P31645 2/20 0.32
MIF P14174 1/20 0.31
SRC P12931 2/20 0.30
MAPT P10636 1/20 0.30
ABL1 P00519 1/20 0.30
RIN1 Q13671 1/20 0.30
TDP1 Q9NUW8 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2918795 0.91 CYP1A2 (0.38) CYP1A2POLBMGAMGAASI
SCHEMBL2918910 0.84 BRD4 (0.30)
SCHEMBL5100727 0.79 POLB (0.43) CYP1A2POLBSMN1; SMN2MGAMGAA
SCHEMBL5100837 0.79 POLB (0.43) CYP1A2POLBSMN1; SMN2MGAMGAA
SCHEMBL5100832 0.79 POLB (0.43) CYP1A2POLBSMN1; SMN2MGAMGAA
SCHEMBL2918359 0.78 DPP4 (0.32)
SCHEMBL1257417 0.78 POLB (0.45) CYP1A2POLBSMN1; SMN2MGAMGAA
Hydrochloric Acid SCHEMBL15157364 0.78 POLB (0.42) CYP1A2POLBSMN1; SMN2MGAMGAA
Hydrochloric Acid SCHEMBL15157362 0.78 POLB (0.42) CYP1A2POLBSMN1; SMN2MGAMGAA
SCHEMBL1257413 0.78 POLB (0.45) CYP1A2POLBSMN1; SMN2MGAMGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1591443-B1 PYRAZOLE DERIVATIVE DAIICHI SANKYO CO LTD (JP) 2010-08-25 EP disclosed
US-7622471-B2 Pyrazole derivatives having a pyridazine and pyridine functionality DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2009-11-24 US disclosed
US-20060189591-A1 Five-membered heterocyclic derivative DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-08-24 US disclosed
US-20060128685-A1 Pyrazole derivative DAIICHI PHARMACEUTICAL CO., LTD., (JP) 2006-06-15 US disclosed
EP-1621537-A1 FIVE-MEMBERED HETEROCYCLIC DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-02-01 EP disclosed
EP-1591443-A1 PYRAZOLE DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2005-11-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060128685-A1 Pyrazole derivative PTGS1, PTGS2, PTGER1 CYP1A2 176/4885POLB 3329/4885SMN1; SMN2 3778/4885
US-20060189591-A1 Five-membered heterocyclic derivative PTGS1, PTGIS, PTGS2 CYP1A2 292/4885POLB 3819/4885SMN1; SMN2 3027/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.